Botanix Pharmaceuticals マネジメント

マネジメント基準チェック /14

Botanix Pharmaceuticalsの CEO はHowie McKibbonで、 Aug2023年に任命され、の在任期間は 1.25年です。の年間総報酬はA$ 3.92Mで、 15.3%給与と84.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.22%を直接所有しており、その価値はA$ 1.42M 。経営陣と取締役会の平均在任期間はそれぞれ1年と5.3年です。

主要情報

Howie McKibbon

最高経営責任者

AU$3.9m

報酬総額

CEO給与比率	15.3%
CEO在任期間	1.3yrs
CEOの所有権	0.2%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

CEO報酬分析

Botanix Pharmaceuticals の収益と比較して、Howie McKibbon の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$4m	AU$602k	-AU$14m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$10m
Sep 30 2023	n/a	n/a	-AU$10m
Jun 30 2023	AU$1m	AU$542k	-AU$9m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$12m
Jun 30 2022	AU$585k	AU$126k	-AU$13m

報酬と市場: Howieの総報酬 ($USD 2.54M ) は、 Australian市場 ($USD 927.07K ) の同規模の企業の平均を上回っています。

報酬と収益: Howieの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Howie McKibbon

1.3yrs

在職期間

AU$3,923,813

報酬

Dr. Howie McKibbon serves as Chief Executive Officer since August 24, 2023 and was its Chief Operating Officer since October 2022 until August 24, 2023. He served as Chief Commercial Officer at Botanix Pha...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Vincent Ippolito	MD & Executive Chairman	5.3yrs	AU$612.70k	0.59% A$ 3.8m
Howie McKibbon	Chief Executive Officer	1.3yrs	AU$3.92m	0.22% A$ 1.4m
Graeme Morissey	Chief Financial Officer	less than a year	AU$186.22k	データなし
Matthew Callahan	Executive Director	4.8yrs	AU$357.12k	4.1% A$ 26.5m
Jack Hoblitzell	Senior Vice President of Pharmaceutical Development	3.8yrs	データなし	データなし
Patricia Walker	Chief Medical Adviser	2.8yrs	データなし	データなし
Boris Meyerson	Chief Business Officer	less than a year	データなし	データなし
David Morgan	Head of Corporate Affairs	less than a year	データなし	データなし
Kevin Wojciechowski	Head of HCP Marketing & Sales Training	less than a year	データなし	データなし
Susan Park	Company Secretary	1.6yrs	データなし	データなし
Darin Van Arsdale	Director of Sales Operations	less than a year	データなし	データなし

1.0yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: BOTの経営陣は経験豊富とはみなされません ( 1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Vincent Ippolito	MD & Executive Chairman	5.3yrs	AU$612.70k	0.59% A$ 3.8m
Matthew Callahan	Executive Director	4.8yrs	AU$357.12k	4.1% A$ 26.5m
Stewart Washer	Independent Non-Executive Director	5.8yrs	AU$61.57k	0.12% A$ 770.4k
Henry Bosch	Non Executive Director	8.3yrs	AU$227.16k	1.04% A$ 6.7m
Daniel Sharp	Non-Executive Director	2.7yrs	AU$88.49k	0.12% A$ 756.6k

5.3yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: BOTの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Botanix Pharmaceuticals マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14